Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics

Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

BioInnovation Institute Boosts Six Life Science Companies

The Venture House initiative aims at propelling former Venture Lab participants into the next phase of their development. “These six companies have...

Germany boosts protein transition with €38m

Germany is set to follow countries such as the Denmark, the UK and the Netherlands, which this year provided massive funding  to become world...

Breakthrough in microtia treatment

Researchers of the Tissue Engineering and Biofabrication Laboratory of the ETH Zurich unveiled a novel approach to addressing microtia, a congenital...

Quotient Therapeutics kicks-off with US$50m financing

Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...

microRNA could offer a safe target in atherosclerosis

The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

CPHI: Trends shaping pharma's path

Despite challenges such as funding slowdowns for biotechs and concerns about high inflation, the industry remains cautiously optimistic,...